Rivanna Medical featured in Daily Progress
HemoShear closes $4M funding round
HemoShear closes $1 million dollar debt financing
HemoSonics received $100,000 in funding from CIT
HemoShear featured in Daily Progress news
The Center for Innovative Technology (CIT) recently announced its grant awards for Fall 2011. Several Coulter funded start-up companies were awarded funds through the Commonwealth Commercialization Research Fund.
- HemoSonics, LLC - $100,000 in SBIR matching funds
HemoSonics is a company focused on the use of ultrasound to diagnose blood-clotting disorders. (hemosonics.com)
- iTi Health, Inc., - $100,000 in SBIR matching funds
iTi has developed a platform technology, Phagemark, that identifies and develops biomarkers and binding peptides to create targeted therapeutics and diagnostic imaging tools.
- HemoShear, LLC - $500,000 through the commercialization program
HemoShear has developed a recalibration process to return the function of cultured cells to their in-vivo characteristics by applying region specific hemodynamic forces. This grant was awarded for work on a project entitled “Interspecies Drug-Induced Vascular Injury (DIVI) Consortium”. (www.hemoshear.com/)
- RetiVue, LLC - $250,000 through the commercialization program
RetiVue was awarded the funding for its project entitled "Bringing Affordable Retinal Screening Technology and Services to the Primary Care Clinic" that is working to commercialize a retinal camera to diagnose and prevent the onset of blindness. (www.retivue.com/)
The grants awarded were part of the $3.6 million that CIT distributed to start-up companies in Virginia this year. More information on the awards is available at www.prweb.com/releases/2011/12/prweb9053447.htm.
FDA To Companion DX Developers: Pre-Trial Assay Validation is Key (pdf)
May 3, 2011
The Wallace H. Coulter Foundation Translational Research Partnership Award Creates a $20 Million U.Va. Endowment for Translational Research in Biomedical Innovation. Read more...
December 3, 2010
Twelve UVa-related biotechnology firms were awarded over $2.7 million in grants under the new Qualified Therapeutic Discovery Project Program. To read more, please visit UVa Today.
Fund Established to Support Biomedical Innovation and Research at U.Va.
March 20, 2008: The University of Virginia's Department of Biomedical Engineering has been selected by Johnson & Johnson as the recipient of a grant to finance biomedical translational research, which will promote the advancement of treatments to improve patient care.
Fund Established to Support Biomedical Innovation and Research at U.Va. (pdf)
Coulter ROPe Funds
Coulter Partnership announces new and innovate source of funds to support faculty translational research. Coulter ROPE Funds (pdf)